RLMD 3.61 Relmada Therapeutics, Inc.
| Range: | 1.88-7.223 | Vol Avg: | 180625 | Last Div: | 0 | Changes: | 0.12 |
| Beta: | 0.51 | Cap: | 0.11B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 20 2014 | Empoloyees: | 20 | ||
| CUSIP: | 75955J402 | CIK: | 0001553643 | ISIN: | US75955J4022 | Country: | US |
| CEO: | Dr. Sergio Traversa M.B.A., Pharm.D. | Website: | https://www.relmada.com | ||||
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Stock Details
RLMD 2
Goldman Sachs Downgrades Relmada Therapeutics Inc (RLMD) to Sell
Andrea Tan·Wed Jun 05 2024
Goldman Sachs
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow